CVS to Cover Lilly’s GLP-1 Medications, Expanding Access
CVS Health will broaden coverage for Lilly’s GLP-1 medications, including the new pill Foundayo and Zepbound injectio...
Brief look at how volume relates to index chart moves, demonstrating how volume spikes can confirm or warn against breakout signals.
28,655 articlesCVS Health will broaden coverage for Lilly’s GLP-1 medications, including the new pill Foundayo and Zepbound injectio...
WTRG just released its quarterly earnings, and the market is parsing revenue growth, margins, and forward guidance. T...
A notable institutional purchase in Plains GP Holdings hints at a larger, value-driven view of the energy midstream s...
IonQ stunned traders with a sharp rally after reporting stronger-than-expected 2025 results and a robust 2026 revenue...
Iovance Biotherapeutics has shown dramatic swings, with recent gains masking a long history of volatility. This piece...
As lawmakers push hundreds of AI bills, a lack of universal testing leaves companies and investors facing a maze of r...
Trading on world prediction markets before kickoff has eclipsed $2 billion, with Spain and France trading as the lead...
Lilly leads the GLP-1 obesity wave as Pfizer rebuilds with deals and repurposed assets. Q1 2026 results underscore tw...
Housing affordability deteriorates as starter homes in dozens of metros breach seven-figure prices. A new study shows...
Ethereum edges higher ahead of a major network upgrade, with an analyst signaling potential upside as on-chain use st...
As AI infrastructure spending stays robust, memory names SanDisk and Micron pursue starkly different paths. SanDisk l...
Myro (MYRO) faces a high-volatility path as traders eye 2025 to 2030 targets. This report lays out the price scenario...